COVACTA trial of tocilizumab in patients hospitalised with severe COVID-19-related pneumonia fails to meet primary end

Roche announced 330-patient trial did not meet primary end-point of improved clinical status in these patients, or key secondary end-point of reduced patient mortality. The news follows an Italian study of the drug that did not show efficacy in early-stage COVID-19 pneumonia.

SPS commentary:

The tocilizumab arm of the RECOVERY trial is continuing for the moment as that is investigating the use of tocilizumab for sicker patients, whereas the Roche trial involved patients with milder disease.


Reuters Health

Resource links:

RECOVERY trial report